BeiGene (BGNE) stock falls as the company halts its lung cancer therapy trial after disappointing safety and efficacy data. .

for treating leptomeningeal metastases (“LM”) in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement. The FDA grants ODD ...

University Hospitals plans to compare Qure.ai’s lung cancer algorithm against radiologists’ X-ray interpretations.